![]() However, the interpretation of ABUS exams, with up to 2,000 images per case, is complex and time consuming, particularly for new users. Results from several clinical studies have shown that the addition of ABUS to screening mammography results in a significant increase in cancer detection in women with dense breasts. However, it was important that we implement with concurrent decision support from QVCAD to improve reading times while maintaining workflow and diagnostic confidence,” said Liz Palomino, MHA, RT, Northern Arizona Healthcare director of medical imaging, Flagstaff Medical Center, Sedona Medical Center, Verde Valley Medical Center and Verde Valley Medical Imaging Center. “We are excited to add the capability to offer ABUS as part of our comprehensive breast cancer screening program, which will help improve cancer detection for women with dense breasts. ![]() Invenia ABUS is approved by the FDA for breast cancer screening as an adjunct to mammography for asymptomatic women with dense breasts. In addition, QView successfully completed an installation of QVCAD at Northern Arizona Healthcare, the first joint installation with the Invenia ABUS system from GE Healthcare. Being demonstrated for the first time since being approved, QVCAD reduces interpretation time of screening ABUS exams while maintaining diagnostic accuracy. Food and Drug Administration (FDA)-approved artificial intelligence (AI) computer-aided detection (CAD) system for concurrent reading of automated breast ultrasound (ABUS) exams, at the 104th Annual Radiological Society of North America (RSNA) meeting, Nov. ![]() Novem– QView Medical will showcase QVCAD, the first U.S.
0 Comments
Leave a Reply. |